Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT06371820 |
Other study ID # |
2014/1287-31/4 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 1, 1965 |
Est. completion date |
May 17, 2043 |
Study information
Verified date |
April 2024 |
Source |
Karolinska Institutet |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The ESPRESSO study is a collection of data from all computerised gastrointestinal
histopathology reports in Sweden. This allows us to study risk factors for gastrointestinal
disease, as well as the prognosis of gastrointestinal disease.
A review of the study has been published here:
https://pubmed.ncbi.nlm.nih.gov/30679926/
Description:
The ESPRESSO study constitutes a novel approach to examine the etiology and prognosis of
gastrointestinal disease in which histopathology plays a prominent role. Between 2015 and
2017, all pathology departments (n=28) in Sweden were contacted and asked to procure
histopathology record data from the gastrointestinal tract (pharynx to anus), liver,
gallbladder, and pancreas. For each individual, local histopathology IT personnel retrieved
data on personal identity number, date of histopathology, topography (where the biopsy is
taken), morphology (biopsy appearance), and where available free text. In total, between 1965
and 2017, histopathology record data were available in 2.1 million unique individuals, but
the number of data entries was 6.1 million because more than one biopsy was performed in many
of the study participants. Index individuals with histopathology data were matched with up to
five controls from the general population. The investigators also identified all first-degree
relatives (parents, children, full siblings), and the index individual's first spouse. The
total study population consisted of 13.0 million individuals. Data from all the study
participants have been linked to Swedish National Healthcare Registers allowing research not
only on such aspects as fetal and perinatal conditions and the risk of future
gastrointestinal disease but also on the risk of comorbidity and complications (including
cancer and death). Furthermore, the ESPRESSO database allows researchers and practitioners to
identify diagnoses and disease phenotypes not currently indexed in national registers
(including disease precursors). The ESPRESSO database increases the sensitivity and
specificity of already-recorded diseases in the national health registers. This paper is an
overview of the ESPRESSO database.